The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial.

Numerically lower proportions of participants with ANA+ who received pirfenidone than who received placebo had decline in %FVC or death, or decline in FVC volume or death, although this difference did not reach statistical significance for either endpoint (%FVC or death: pirfenidone 37.2% vs. placebo 48.7%, P = 0.093; FVC volume or death: pirfenidone 35.7% vs. placebo 48.7%, P = 0.053) (Fig. 3 ).

also in 111,027 other papers